PureTech Health (PRTC) said Wednesday that topline results from a phase 1b trial evaluating LYT-200 in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia showed "robust" antileukemic activity and a "favorable" safety profile.

The company said that LYT-200 combined with a hypomethylating agent delivered complete responses, bridging to transplant, and durable clinical benefit.

LYT-200 also demonstrated a consistent safety profile across all cohorts and dose levels studied, the company said.

The company said its Gallop Oncology unit has selected a recommended dose for a phase 2 study in relapsed/refractory high-risk myelodysplastic syndrome and plans to engage with the US Food and Drug Administration to discuss trial design.

Price: 18.04, Change: +0.04, Percent Change: +0.22